Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: AML2003 - Randomized Comparison Between Standard-Therapy and Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years. A Prospective, Randomized, Multi-center Therapy-Optimizing-Study.
Brief Summary: AML2003 is a prospective randomized trial, to investigate the value of early allogeneic stem cell transplantation in aplasia after induction therapy for high risk patients with acute myeloid leukemia.


Options:
A: Arm Label: Decitabine; Type: EXPERIMENTAL; Interventions: Drug: Decitabine | Arm Label: Decitabine+VPA; Type: EXPERIMENTAL; Interventions: Drug: Decitabine, Drug: VPA | Arm Label: Decitabine+ATRA; Type: EXPERIMENTAL; Interventions: Drug: Decitabine, Drug: ATRA | Arm Label: Decitabine+VPA+ATRA; Type: EXPERIMENTAL; Interventions: Drug: Decitabine, Drug: VPA, Drug: ATRA | Intervention Type: DRUG; Name: Decitabine; Assigned to Arm(s): Decitabine, Decitabine+ATRA, Decitabine+VPA, Decitabine+VPA+ATRA | Intervention Type: DRUG; Name: VPA; Assigned to Arm(s): Decitabine+VPA, Decitabine+VPA+ATRA | Intervention Type: DRUG; Name: ATRA; Assigned to Arm(s): Decitabine+ATRA, Decitabine+VPA+ATRA
B: Intervention Type: DRUG; Name: Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: early allogeneic PBSCT within induction therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: autologous PBSCT; Assigned to Arm(s): N/A
C: Arm Label: Standard Daunorubicin Then Autologous HCT; Type: EXPERIMENTAL; Interventions: Biological: sargramostim, Drug: busulfan, Drug: cyclophosphamide, Drug: cytarabine, Drug: Daunorubicin, Procedure: Autologous HCT | Arm Label: High-dose Daunorubicin Then Autologous HCT; Type: EXPERIMENTAL; Interventions: Biological: sargramostim, Drug: busulfan, Drug: cyclophosphamide, Drug: cytarabine, Drug: Daunorubicin, Procedure: Autologous HCT | Arm Label: Standard Daunorubicin Then GO/Autologous HCT; Type: EXPERIMENTAL; Interventions: Biological: sargramostim, Drug: busulfan, Drug: cyclophosphamide, Drug: cytarabine, Drug: gemtuzumab ozogamicin (GO), Drug: Daunorubicin, Procedure: Autologous HCT | Arm Label: High-dose Daunorubicin Then GO/Autologous HCT; Type: EXPERIMENTAL; Interventions: Biological: sargramostim, Drug: busulfan, Drug: cyclophosphamide, Drug: cytarabine, Drug: gemtuzumab ozogamicin (GO), Drug: Daunorubicin, Procedure: Autologous HCT | Arm Label: Standard Daunorubicin Then Allogeneic HCT or no Consolidation; Type: ACTIVE_COMPARATOR; Interventions: Drug: cytarabine, Drug: Daunorubicin, Procedure: Allogeneic HCT | Arm Label: High-dose Daunorubicin Then Allogeneic HCT or no Consolidation; Type: EXPERIMENTAL; Interventions: Drug: cytarabine, Drug: Daunorubicin, Procedure: Allogeneic HCT | Intervention Type: BIOLOGICAL; Name: sargramostim; Assigned to Arm(s): High-dose Daunorubicin Then Autologous HCT, High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: DRUG; Name: busulfan; Assigned to Arm(s): High-dose Daunorubicin Then Autologous HCT, High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): High-dose Daunorubicin Then Autologous HCT, High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: DRUG; Name: cytarabine; Assigned to Arm(s): High-dose Daunorubicin Then Allogeneic HCT or no Consolidation, High-dose Daunorubicin Then Autologous HCT, High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then Allogeneic HCT or no Consolidation, Standard Daunorubicin Then Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: DRUG; Name: gemtuzumab ozogamicin (GO); Assigned to Arm(s): High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: DRUG; Name: Daunorubicin; Assigned to Arm(s): High-dose Daunorubicin Then Allogeneic HCT or no Consolidation, High-dose Daunorubicin Then Autologous HCT, High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then Allogeneic HCT or no Consolidation, Standard Daunorubicin Then Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: PROCEDURE; Name: Autologous HCT; Assigned to Arm(s): High-dose Daunorubicin Then Autologous HCT, High-dose Daunorubicin Then GO/Autologous HCT, Standard Daunorubicin Then Autologous HCT, Standard Daunorubicin Then GO/Autologous HCT | Intervention Type: PROCEDURE; Name: Allogeneic HCT; Assigned to Arm(s): High-dose Daunorubicin Then Allogeneic HCT or no Consolidation, Standard Daunorubicin Then Allogeneic HCT or no Consolidation
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cytarabine, Drug: Idarubicin, Drug: Etoposide, Drug: Pegfilgrastim | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Cytarabine, Drug: Idarubicin, Drug: Etoposide, Drug: All-trans retinoic acid, Drug: Pegfilgrastim | Intervention Type: DRUG; Name: Cytarabine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Idarubicin; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: All-trans retinoic acid; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Pegfilgrastim; Assigned to Arm(s): 1, 2

Answer: B